The Runx transcriptional co-activator, CBFβ, is essential for invasion of breast cancer cells
Open Access
- 30 June 2010
- journal article
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 9 (1), 171
- https://doi.org/10.1186/1476-4598-9-171
Abstract
Background The transcription factor Runx2 has an established role in cancers that metastasize to bone. In metastatic breast cancer cells Runx2 is overexpressed and contributes to the invasive capacity of the cells by regulating the expression of several invasion genes. CBFβ is a transcriptional co-activator that is recruited to promoters by Runx transcription factors and there is considerable evidence that CBFβ is essential for the function of Runx factors. However, overexpression of Runx1 can partially rescue the lethal phenotype in CBFβ-deficient mice, indicating that increased levels of Runx factors can, in some situations, overcome the requirement for CBFβ. Since Runx2 is overexpressed in metastatic breast cancer cells, and there are no reports of CBFβ expression in breast cells, we sought to determine whether Runx2 function in these cells was dependent on CBFβ. Such an interaction might represent a viable target for therapeutic intervention to inhibit bone metastasis. Results We show that CBFβ is expressed in the metastatic breast cancer cells, MDA-MB-231, and that it associates with Runx2. Matrigel invasion assays and RNA interference were used to demonstrate that CBFβ contributes to the invasive capacity of these cells. Subsequent analysis of Runx2 target genes in MDA-MB-231 cells revealed that CBFβ is essential for the expression of Osteopontin, Matrixmetalloproteinase-13, Matrixmetalloproteinase-9, and Osteocalcin but not for Galectin-3. Chromatin immunoprecipitation analysis showed that CBFβ is recruited to both the Osteopontin and the Galectin-3 promoters. Conclusions CBFβ is expressed in metastatic breast cancer cells and is essential for cell invasion. CBFβ is required for expression of several Runx2-target genes known to be involved in cell invasion. However, whilst CBFβ is essential for invasion, not all Runx2-target genes require CBFβ. We conclude that CBFβ is required for a subset of Runx2-target genes that are sufficient to maintain the invasive phenotype of the cells. These findings suggest that the interaction between Runx2 and CBFβ might represent a viable target for therapeutic intervention to inhibit bone metastasis.Keywords
This publication has 34 references indexed in Scilit:
- Is Runx a linchpin for developmental signaling in metazoans?Journal of Cellular Biochemistry, 2009
- RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumorsEndocrine, 2008
- Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical managementJournal of Cellular Biochemistry, 2007
- Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with boneCancer and Metastasis Reviews, 2006
- A role for Runx2 in normal mammary gland and breast cancer bone metastasisJournal of Cellular Biochemistry, 2005
- Smad3 Interacts with JunB and Cbfa1/Runx2 for Transforming Growth Factor-β1-stimulated Collagenase-3 Expression in Human Breast Cancer CellsOnline Journal of Public Health Informatics, 2004
- Homologs of RUNX and CBFβ/PEBP2β in C. elegansOncogene, 2004
- Core-binding factor β interacts with Runx2 and is required for skeletal developmentNature Genetics, 2002
- Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cellsOncogene, 1999
- AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver HematopoiesisCell, 1996